已收盤 09-19 16:00:00 美东时间
+1.640
+1.90%
Emergent BioSolutions has secured over $250 million in contract modifications from the ASPR at the U.S. Department of Health and Human Services. The funding ensures the supply of critical medical countermeasures, including Cyfendus for anthrax, ACAM2000 for smallpox, VIGIV for smallpox vaccine complications, and BAT for botulism.
07-03 18:11
Meituan reported (24 Aug) its 2Q23 results: revenue was RMB68.0bn, up 33% YoY, ...
2023-08-25 13:22
Cowen & Co.:维持Emergent BioSolutions Inc.(EBS.US)大市一致评级, 目标价由30.00美元调整至29.00美...
2022-09-12 22:17